# Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

> **NCT01950390** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 169 (actual)

## Conditions studied

- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
- Unresectable Melanoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT01950390
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-24
- **Primary completion:** 2021-10-06
- **Final completion:** 2025-01-31
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01950390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01950390, "Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01950390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*